Compare RHI & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RHI | IDYA |
|---|---|---|
| Founded | 1948 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.6B |
| IPO Year | 1994 | 2019 |
| Metric | RHI | IDYA |
|---|---|---|
| Price | $30.82 | $28.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 16 |
| Target Price | $30.33 | ★ $52.86 |
| AVG Volume (30 Days) | ★ 1.8M | 784.1K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 8.68% | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $5,378,506,000.00 | $218,710,000.00 |
| Revenue This Year | $1.27 | N/A |
| Revenue Next Year | $5.95 | $201.05 |
| P/E Ratio | $221.07 | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $21.83 | $20.50 |
| 52 Week High | $45.17 | $39.28 |
| Indicator | RHI | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 63.52 | 45.42 |
| Support Level | $25.93 | $26.05 |
| Resistance Level | $35.37 | $30.18 |
| Average True Range (ATR) | 1.44 | 1.33 |
| MACD | 0.34 | 0.12 |
| Stochastic Oscillator | 82.35 | 12.24 |
Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.